4.7 Article

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers

期刊

BRITISH JOURNAL OF CANCER
卷 120, 期 9, 页码 922-930

出版社

SPRINGERNATURE
DOI: 10.1038/s41416-019-0427-4

关键词

-

类别

资金

  1. Academy of Finland (Centre of Excellence in Cancer Genetics Research 2012-2017) [250345]
  2. Academy of Finland (Centre of Excellence in Tumor Genetics Research 2018-2023) [312041]
  3. Finnish Cancer Society
  4. Sigrid Juselius Foundation
  5. Jane and Aatos Erkko Foundation
  6. Academy of Finland [295693]
  7. Ida Montin Foundation
  8. Juhani Aho Foundation for Medical Research
  9. Biomedicum Helsinki Foundation
  10. Finnish Medical Society Duodecim
  11. Paivikki and Sakari Sohlberg Foundation
  12. Einar and Karin Stroem Foundation
  13. Emil Aaltonen Foundation
  14. Oskar Oflund Foundation
  15. Finnish-Norwegian Medical Foundation
  16. Gastroenterological Research Foundation
  17. Maud Kuistila Memorial Foundation
  18. K. Albin Johansson Foundation
  19. Orion-Pharmos Research Foundation
  20. Academy of Finland (AKA) [295693, 295693] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

BACKGROUND: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches. METHODS: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion and mutation profile in both lesions of an individual. RESULTS: The tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden. CONCLUSIONS: The study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the need to evaluate both tumours of a synchronous pair for optimised targeted therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据